The clinical exploitation of type I interferon (IFN) as an antiviral and antineoplastic agent is based on the properties originally attributed to this cytokine family, with schedules reflecting only their antiviral and antiproliferative activities. Nevertheless, type I IFN has emerged as a central activator of the innate immunity. As current schedules of treatment for chronic hepatitis C and for hematological and solid tumors, based on the continuous administration of recombinant type I IFN or pegylated formulations, disregard viral resistance, host genetic variants predicting treatment outcome and mechanisms of refractoriness, new administration schedules, the combination of type I IFN with new drugs and the increased monitoring of patients' susceptibility to type I IFN are expected to provide a new life to this valuable cytokine.

Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use / Antonelli, Guido; Scagnolari, Carolina; Federica, Moschella; Enrico, Proietti. - In: CYTOKINE & GROWTH FACTOR REVIEWS. - ISSN 1359-6101. - STAMPA. - 26:(2015), pp. 121-131. [10.1016/j.cytogfr.2014.12.006]

Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use

ANTONELLI, Guido;SCAGNOLARI, CAROLINA;
2015

Abstract

The clinical exploitation of type I interferon (IFN) as an antiviral and antineoplastic agent is based on the properties originally attributed to this cytokine family, with schedules reflecting only their antiviral and antiproliferative activities. Nevertheless, type I IFN has emerged as a central activator of the innate immunity. As current schedules of treatment for chronic hepatitis C and for hematological and solid tumors, based on the continuous administration of recombinant type I IFN or pegylated formulations, disregard viral resistance, host genetic variants predicting treatment outcome and mechanisms of refractoriness, new administration schedules, the combination of type I IFN with new drugs and the increased monitoring of patients' susceptibility to type I IFN are expected to provide a new life to this valuable cytokine.
File allegati a questo prodotto
File Dimensione Formato  
Antonelli_twenty-five_2015.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.63 MB
Formato Adobe PDF
1.63 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/780422
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 36
social impact